Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.

ABSTRACT:

Background

Japanese guidelines recommend triple therapy with vonoprazan or a proton pump inhibitor (PPI) in combination with antibiotics to treat Helicobacter pylori (H. pylori) infection. While studies have shown improved eradication rates and reduced costs with vonoprazan versus PPIs, there is little data describing healthcare resource use (HCRU) and treatment patterns.

Objectives

To compare patients treated with a vonoprazan-based or PPI-based regimen for H. pylori infection in Japan in terms of their characteristics, HCRU, healthcare costs, clinical outcomes, and treatment patterns.

Design

Retrospective matched cohort.

Methods

We used data from the Japan Medical Data Center claims database (July 2014-January 2020) to identify adu

SUBMITTER: Howden CW 

PROVIDER: S-EPMC10161293 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature